Who are BioNTech?
CPHI lifts the lid on the relatively little known German biotech and partner of Pfizer behind the most promising COVID19 vaccine candidate
BioNTech was founded in 2008 in Mainz, Germany, by husband and wife, Uğur Şahin, and Özlem Türeci, – both German scientists of Turkish origin-- and Austrian oncologist Christoph Huber, with a vision to develop pioneering therapeutics for cancer and other serious diseases.
In terms of R&D, the clinical-stage company’s key breakthrough came in August 2018, when it announced it had agreed a multi-year collaboration with Pfizer to develop mRNA-based vaccines for the prevention of influenza. Under this agreement, Pfizer was to assume sole responsibility for further clinical development and commercialization of the vaccines after BioNTech’s completion of a first in human clinical study.
In September 2019, BioNTech announced it had secured an initial investment of USD55 million via the Bill & Melinda Gates Foundation to develop HIV and tuberculosis programs, further expanding the company’s infectious disease portfolio. A further USD45 million under the collaboration could be realised through potential future grant funding.
But it was not until 2020 that the company really started grabbing the headlines as its mRNA-based work began to pay off. In March, it signed a letter of intent with Pfizer to co-develop and distribute BioNTech’s potential COVID-19 vaccine, BNT162, globally. That deal excluded China where BioNTech had already partnered with Fosun Pharma to develop the vaccine.
Development of the vaccine quickly gathered pace, with approval to conduct Phase I/I trials gained in April, and first participants dosed in the US in May. And in June, the European Investment Bank agreed to provide EUR 100 million of debt financing to support the development of the vaccine programme, allowing BioNTech to expand its manufacturing capacity in order to supply the vaccine globally.
This was dwarfed in September when the German Federal Ministry of Education and Research awarded a grant of up to EUR 375 million to BioNTech to support accelerated development of SARS-CoV-2 vaccines. That same month, BioNTech announced it had agreed to buy Novartis’ manufacturing facility in Marburg, Germany with a view to expanding its COVID-19 vaccine production capacity by up to 750 million doses per year, once fully operational.
With the announcement in November that preliminary data indicates BNT162b2 is more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection – and several large BNT162 distribution deals already signed with major countries including the US, Japan, the UK and most recently the European Union -- BioNTech now seems set to become a household name.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor... -
News Gerresheimer predicts weight-loss drug deals to account for 4% of yearly growth
Dietmar Siemssen, CEO of German primary packaging manufacturer Gerresheimer, states that approximately 4% of the company’s revenue growth each year to come from deals with drugmakers of weight loss and diabetes products, particularly GLP-1 class ... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Coronary drug-coated medical device receives US FDA approval
Boston Scientific announced the FDA approval of their medical device AGENT Drug-Coated Balloon (DCB) for the indication of coronary in-stent restenosis in coronary artery disease patients. -
News CPHI Online Webinar Series – Innovative Strategies for B2B Pharma Marketeers
On February 20, 2024, CPHI Online hosted a webinar on Innovative Strategies for B2B Pharma Marketeers. Featuring expert speakers from across the pharmaceutical value chain, this webinar delves into how B2B pharma marketeers can create better content to... -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance